X4 Pharmaceuticals, Inc. (XFOR)
2.77
-0.13
(-4.48%)
USD |
NASDAQ |
Oct 06, 16:00
X4 Pharmaceuticals EPS Diluted (Quarterly) : -0.1279 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1279 |
| March 31, 2026 | -0.1603 |
| December 31, 2025 | -0.2164 |
| September 30, 2025 | -0.689 |
| June 30, 2025 | -3.472 |
| March 31, 2025 | 0.0411 |
| December 31, 2024 | -5.887 |
| September 30, 2024 | -0.1827 |
| June 30, 2024 | 0.4524 |
| March 31, 2024 | -0.2588 |
| December 31, 2023 | -0.0962 |
| September 30, 2023 | -0.0117 |
| June 30, 2023 | -0.3302 |
| March 31, 2023 | -0.1646 |
| December 31, 2022 | -0.2888 |
| September 30, 2022 | -0.2629 |
| June 30, 2022 | -0.5986 |
| March 31, 2022 | -0.718 |
| December 31, 2021 | -1.238 |
| September 30, 2021 | -0.7582 |
| June 30, 2021 | -0.7403 |
| Date | Value |
|---|---|
| March 31, 2021 | -1.297 |
| December 31, 2020 | -0.9121 |
| September 30, 2020 | -0.8688 |
| June 30, 2020 | -0.756 |
| March 31, 2020 | -0.5565 |
| December 31, 2019 | -0.6581 |
| September 30, 2019 | -1.216 |
| June 30, 2019 | -1.016 |
| March 31, 2019 | -6.674 |
| December 31, 2018 | -4561.78 |
| September 30, 2018 | -611.64 |
| June 30, 2018 | -16019.25 |
| March 31, 2018 | -19118.15 |
| December 31, 2017 | -1816.71 |
| September 30, 2017 | -24411.91 |
| June 30, 2017 | -14.40 |
| March 31, 2017 | -13.58 |
| December 31, 2016 | -402.47 |
| September 30, 2016 | -680.07 |
| June 30, 2016 | -390.39 |
| March 31, 2016 | -8.827 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Sarepta Therapeutics, Inc. | -0.0464 |
| Arrowhead Pharmaceuticals, Inc. | -1.355 |
| Oncolytics Biotech, Inc. | -0.0788 |
| Sangamo Therapeutics, Inc. | -0.0796 |
| Anixa Biosciences, Inc. | -0.0762 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -16.16M |
| Revenue (Quarterly) | 8.806M |
| Total Expenses (Quarterly) | 24.96M |
| Enterprise Value | 134.91M |
| Gross Profit Margin (Quarterly) | 81.24% |
| Profit Margin (Quarterly) | -183.5% |
| Earnings Yield | -43.09% |
| Normalized Earnings Yield | -42.81 |